Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,861 to 3,880 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| With Complications vs Without Complications: Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments. | 528 of 637 981 of 1,128 | -4.1 points -7.7 to -0.6 | 1,765 | NCT00605865 Drug Use Investigation of Jzoloft. |
| 15 Years and Higher vs Under 15 Years: Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not | 1,508 of 1,762 1 of 3 | 52.3 points 6.3 to 79.5 | 1,765 | NCT00605865 Drug Use Investigation of Jzoloft. |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Number of Children for Whom an EEG Was Ordered | 6 of 879 22 of 885 | -1.8 points -3.1 to -0.6 | 1,764 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Diagnostic Accuracy | 846 of 879 826 of 885 | 2.9 points 0.8 to 5.0 | 1,764 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Early-ART vs Delayed-ART: serious adverse events | 526 of 886 522 of 877 | -0.2 points -4.7 to 4.4 | 1,763 | NCT00074581 Preventing Sexual Transmission of HIV With Anti-HIV Drugs |
| Vaccine vs Placebo: serious adverse events | 42 of 1,174 19 of 587 | 0.3 points -1.6 to 2.0 | 1,761 | NCT01797029 A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh |
| Vaccine vs Placebo: serious adverse events | 7 of 1,174 7 of 587 | -0.6 points -1.9 to 0.3 | 1,761 | NCT01854632 Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal |
| Group ANC vs Stand ANC: deaths from any cause | 2 of 877 3 of 884 | -0.1 points -0.8 to 0.5 | 1,761 | NCT04033003 Group Antenatal Care and Delivery Project |
| Group ANC vs Stand ANC: serious adverse events | 2 of 877 3 of 884 | -0.1 points -0.8 to 0.5 | 1,761 | NCT04033003 Group Antenatal Care and Delivery Project |
| Email vs Post: Email vs Postal Recruitment: Number of GPs Completing the First Questionnaire | 138 of 880 132 of 880 | 0.7 points -2.7 to 4.1 | 1,760 | NCT01206738 Developing and Evaluating Interventions to Reduce Inappropriate Prescribing of Antibiotics in Primary Care |
| Aliskiren Based Regimen vs Non-Aliskiren Based Regimen: Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen | 11 of 860 14 of 899 | -0.3 points -1.5 to 0.9 | 1,759 | NCT01259297 A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People |
| Aliskiren Based Regimen vs Non-Aliskiren Based Regimen: Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen | 5 of 860 9 of 899 | -0.4 points -1.4 to 0.5 | 1,759 | NCT01259297 A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People |
| Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events | 581 of 878 552 of 878 | 3.3 points -1.2 to 7.8 | 1,756 | NCT00330759 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. |
| Care Transitions Intervention vs Usual Care: Number of Participants Who Died Within 30 Days of Discharge | 2 of 863 5 of 893 | -0.3 points -1.1 to 0.4 | 1,756 | NCT02520661 Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health |
| Nitazoxanide vs Placebo: serious adverse events | 4 of 872 1 of 884 | 0.3 points -0.2 to 1.1 | 1,756 | NCT03605862 Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection |
| Everolimus vs Placebo: serious adverse events | 180 of 874 77 of 881 | 11.9 points 8.6 to 15.1 | 1,755 | NCT01674140 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
| Etanercept vs nbDMARDs: serious adverse events | 77 of 211 534 of 1,543 | 1.9 points -4.8 to 9.0 | 1,754 | NCT01557322 Characterize Patients With Moderately Active Rheumatoid Arthritis (RA) |
| qHPV Vaccine in Base Study vs Placebo in Base Study: Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18 | 6 of 1,165 0 of 584 | 0.5 points -0.2 to 1.1 | 1,749 | NCT00092547 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) |
| qHPV Vaccine in Base Study vs Placebo in Base Study: Number of Participants Reporting Other (Non-serious) AEs Through Month 18 | 918 of 1,165 340 of 584 | 20.6 points 16.0 to 25.2 | 1,749 | NCT00092547 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) |
| Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Injection-Site Adverse Experiences | 701 of 1,415 164 of 334 | 0.4 points -5.5 to 6.4 | 1,749 | NCT00326183 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=194"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=194
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00605865-8d117e32",
"title": "With Complications vs Without Complications: Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments.",
"summary": "528 of 637 against 981 of 1128; risk difference -4.1 points, 95% interval -7.7 to -0.6; NCT00605865, Drug Use Investigation of Jzoloft.",
"record": "/library/comparisons/NCT00605865-8d117e32",
"nct_id": "NCT00605865",
"kind": "outcome",
"participants": 1765,
"risk_difference": {
"value": -0.04079545074985802,
"lower": -0.0770129993696266,
"upper": -0.006446074987908126
},
"group_1": "528 of 637",
"group_2": "981 of 1,128",
"difference": "-4.1 points",
"interval": "-7.7 to -0.6",
"trial_title": "Drug Use Investigation of Jzoloft."
},
{
"id": "NCT00605865-c25a0018",
"title": "15 Years and Higher vs Under 15 Years: Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not",
"summary": "1508 of 1762 against 1 of 3; risk difference 52.3 points, 95% interval 6.3 to 79.5; NCT00605865, Drug Use Investigation of Jzoloft.",
"record": "/library/comparisons/NCT00605865-c25a0018",
"nct_id": "NCT00605865",
"kind": "outcome",
"participants": 1765,
"risk_difference": {
"value": 0.5225122966326146,
"lower": 0.0631840171679276,
"upper": 0.7948024681500782
},
"group_1": "1,508 of 1,762",
"group_2": "1 of 3",
"difference": "52.3 points",
"interval": "6.3 to 79.5",
"trial_title": "Drug Use Investigation of Jzoloft."
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=195",
"request_id": "1VawcfiAAGmp-GGz"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant